References

Management of opioid misuse and opioid use disorders among youth.

10.1542/peds.2019-2056c · 2020 · External reference

Medication for adolescents and young adults with opioid use disorder.

10.1016/j.jadohealth.2020.12.129 · 2021 · External reference

The overdose crisis among U.S. adolescents.

10.1056/nejmp2312084 · 2024 · External reference

Changes in synthetic opioid-involved youth overdose deaths in the United States: 2018-2022.

10.1542/peds.2024-069488 · 2025 · External reference

Polysubstance-involved opioid overdose deaths among US youths: 2020 to 2023.

10.1542/peds.2024-070433 · 2025 · External reference

Drug overdose deaths among persons aged 10-19 years: United States, July 2019-December 2021.

10.15585/mmwr.mm7150a2 · 2022 · External reference

Deaths: leading causes for 2023.

2025 · External reference

Current causes of death in children and adolescents in the United States.

10.1056/nejmc2201761 · 2022 · External reference

Medication-assisted treatment of adolescents with opioid use disorders.

10.1542/peds.2016-1893 · 2016 · External reference

Developing an opioid use disorder treatment cascade: a review of quality measures.

10.1016/j.jsat.2018.06.001 · 2018 · External reference

Performance measurement for opioid use disorder medication treatment and care retention.

10.1176/appi.ajp.20220456 · 2023 · External reference

Opioid use disorder Cascade of care framework design: A roadmap.

10.1080/08897077.2022.2074604 · 2022 · External reference

Access to medications for opioid use disorder and associated factors among adolescents and young adults: a systematic review.

10.1001/jamapediatrics.2021.4606 · 2022 · External reference

The challenges of addressing pediatric quality measurement gaps.

10.1542/peds.2017-0174 · 2017 · External reference

The T-MSIS Analytic Files (TAF) Analysis Reporting Checklist: a guide for research using Medicaid claims data.

10.1001/jamahealthforum.2025.3622 · 2025 · External reference

Receipt of timely addiction treatment and association of early medication treatment with retention in care among youths with opioid use disorder.

10.1001/jamapediatrics.2018.2143 · 2018 · External reference

Use of medications for treatment of opioid use disorder among US Medicaid enrollees in 11 states, 2014-2018.

10.1001/jama.2021.7374 · 2021 · External reference

Buprenorphine treatment duration and adherence among youth and subsequent health outcomes.

10.1542/peds.2025-071147 · 2025 · External reference

Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults, 2001-2014.

10.1001/jamapediatrics.2017.0745 · 2017 · External reference

Buprenorphine dispensing among youth aged =19 years in the United States: 2015-2020.

10.1542/peds.2022-058755 · 2023 · External reference

Pattern of buprenorphine treatment retention among youth aged 10 to 18 years-US, 2015 to 2021.

10.1001/jamapediatrics.2024.2502 · 2024 · External reference

Trends in buprenorphine dispensing among adolescents and young adults in the US.

10.1001/jama.2024.24121 · 2025 · External reference

State- and county-level geographic variation in opioid use disorder, medication treatment, and opioid-related overdose among Medicaid enrollees.

10.1001/jamahealthforum.2023.1574 · 2023 · External reference

Community-based cluster-randomized trial to reduce opioid overdose deaths.

10.1056/nejmoa2401177 · 2024 · External reference

Utilizing SBIRT as a framework for transforming how we think about prevention and early intervention for youth and young adults.

10.1016/j.jadohealth.2021.10.032 · 2022 · External reference

Substance use screening, brief intervention, and referral to treatment.

10.1542/peds.2016-1210 · 2016 · External reference

An exploration of young adults with opioid use disorder and how their perceptions of family members’ beliefs affects medication treatment.

10.1097/adm.0000000000001001 · 2022 · External reference

Treating opioid use disorder in general practice: diagnosis, harm reduction, and medications.

10.1056/nejmp2310171 · 2024 · External reference

A qualitative study of barriers and facilitators to integrating medications for opioid use disorder and HIV preexposure prophylaxis for adolescents and young adults.

10.1097/adm.0000000000001195 · 2023 · External reference

Treatments used among adolescent residential addiction treatment facilities in the US, 2022.

10.1001/jama.2023.6266 · 2023 · External reference

Adolescent residential addiction treatment in the US: uneven access, waitlists, and high costs.

10.1377/hlthaff.2023.00777 · 2024 · External reference

Defining discontinuation for buprenorphine treatment: implications for quality measurement.

10.1176/appi.ajp.20230808 · 2024 · External reference

Association of racial/ethnic segregation with treatment capacity for opioid use disorder in counties in the United States.

10.1001/jamanetworkopen.2020.3711 · 2020 · External reference

Adolescent-serving addiction treatment facilities in the United States and the availability of medications for opioid use disorder.

10.1016/j.jadohealth.2020.03.005 · 2020 · External reference

Opioid use disorder treatment facilities with programs for special populations.

10.1016/j.amepre.2020.03.022 · 2020 · External reference

Perceptions around medications for opioid use disorder among a diverse sample of U.S. adults.

10.1016/j.josat.2024.209361 · 2024 · External reference

Improving substance use prevention, assessment, and treatment financing to enhance equity and improve outcomes among children, adolescents, and young adults.

10.1542/peds.2022-057992 · 2022 · External reference

Telehealth for opioid use disorder: retention as a function of demographics and rurality.

10.1080/00952990.2023.2180382 · 2023 · External reference

Medication for addiction treatment and postpartum health care utilization among pregnant persons with opioid use disorder.

10.1097/adm.0000000000000827 · 2022 · External reference

The impact of Medicaid expansion on postpartum health care utilization among pregnant women with opioid use disorder.

10.1080/08897077.2019.1573209 · 2019 · External reference

Validity of incident opioid use disorder (OUD) diagnoses in administrative data: a chart verification study.

10.1007/s11606-020-06339-3 · 2021 · External reference

Identifying individuals with opioid use disorder: validity of International Classification of Diseases diagnostic codes for opioid use, dependence and abuse.

10.1016/j.drugalcdep.2021.108583 · 2021 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference